Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Stem cell transplantation & cellular therapy during COVID-19 in Europe

Per Ljungman • 5 Feb 2021
TCT 2021
General

Per Ljungman, MD, PhD, Karolinska Institute, Stockholm, Sweden, outlines the impact of the COVID-19 pandemic on stem cell transplantation and cellular therapies in Europe over the last year and reports COVID-19 related mortality in patients undergoing stem cell transplantation and treated with CAR T-cell therapies. Prof. Ljungman highlights risk factors associated with COVID-19 mortality in this patient population, including age, poor performance status, and time from transplant. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Per Ljungman

0:27
What to expect from TCT 2021?
Per Ljungman • 5 Feb 2021
1:30
EBMT Project 2020: migration of data
Per Ljungman • 1 Sep 2020
2:46
Letermovir prevents cytomegalovirus (CMV) in transplant patients
Per Ljungman • 24 Aug 2020
2:11
Impact of COVID-19 on transplantation
Per Ljungman • 20 Aug 2020

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals